Abstract
BACKGROUND: The cumulative incidence and risk of cytomegalovirus (CMV) reactivation in patients with relapsed/refractory multiple myeloma (RRMM) receiving elranatamab remain unclear. METHODS: We retrospectively analyzed RRMM patients treated with elranatamab to assess cumulative incidence and risk factors for CMV reactivation. RESULTS: Among 32 patients, the 6-month cumulative incidence of CMV reactivation was 37.3%. High CMV immunoglobulin G (IgG) titers were significantly associated with CMV reactivation (57.9% vs. 9.1%, p = 0.012), while prophylactic immunoglobulin reduced CMV reactivation risk within high CMV IgG group. CONCLUSION: Baseline CMV IgG titers may help guide risk-adapted monitoring and prevention strategies during elranatamab therapy.